Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 13.2% – Should You Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares rose 13.2% on Thursday . The stock traded as high as $0.37 and last traded at $0.36. Approximately 85,764,556 shares changed hands during trading, an increase of 13% from the average daily volume of 76,209,492 shares. The stock had previously closed at $0.32.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a report on Saturday. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Price Performance

The business has a fifty day moving average price of $0.28 and a 200 day moving average price of $0.28. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market cap of $71.60 million, a price-to-earnings ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. As a group, research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.